Johnson & Johnson Acquires Intra-Cellular in $14.6 Billion Deal
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling medicines to go off patent in the coming weeks.
Yahoo Finance26d
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
NEW BRUNSWICK, N.J. and BEDMINSTER, N.J., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced ...